Comparative Pharmacology
Head-to-head clinical analysis: DEXASPORIN versus NYSTATIN TRIAMCINOLONE ACETONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXASPORIN versus NYSTATIN TRIAMCINOLONE ACETONIDE.
DEXASPORIN vs NYSTATIN-TRIAMCINOLONE ACETONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
Nystatin is a polyene antifungal that binds to ergosterol in the fungal cell membrane, forming pores that cause leakage of intracellular contents and cell death. Triamcinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
Apply topically to affected area twice daily for 2-4 weeks.
None Documented
None Documented
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Nystatin: negligible systemic half-life due to lack of absorption. Triamcinolone acetonide: terminal half-life ~2-5 hours (mean ~3.5 h) after intravascular administration; prolonged in hepatic impairment.
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Nystatin: negligible systemic absorption; excreted unchanged in feces (~100%). Triamcinolone acetonide: metabolized hepatically; renal excretion of metabolites (~40%) and unchanged drug (<5%); fecal excretion (~60%).
Category C
Category D/X
Corticosteroid/Antibiotic Combination
Corticosteroid